ReviewAging and disease2024
Metabolic Dysfunction in Idiopathic Intracranial Hypertension: Current Theories and Updates.
Review in Aging and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Coexistence of acromegaly and raised intracranial pressure: insights from a rare case report and literature review.BMC neurology · 2026Review
- "Just lose weight": weight-based medical bias and experiential expertise in intracranial hypertension.Frontiers in psychiatry · 2026Article
- The association between Chinese visceral adiposity index and hypertension among middle-aged and older population: a cross-sectional study based on CHARLS.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic intracranial hypertension (IIH) is a disease characterized by increased intracranial pressure (ICP) without identifiable secondary causes. While the increased ICP is a critical diagnostic feature, the underlying pathophysiological mechanisms remain unclear. Previous theories have suggested cerebrospinal fluid (CSF) overproduction, impaired reabsorption, or circulatory obstruction as potential causes. Emerging evidence indicates that IIH may not be solely a central nervous system disorder but also a systemic metabolic disorder. Metabolic and hormonal dysregulation features, including hyperleptinemia, adipocyte leptin hypersecretion, increased insulin resistance, and androgen excess, have been noted in IIH. Furthermore, the targeted blockade of the cortisol-producing enzyme 11β-hydroxysteroid dehydrogenase type 1 has demonstrated therapeutic potential in treating IIH. Consequently, the role of metabolic dysfunction and hormonal imbalance in IIH warrants consideration. This review aims to provide a comprehensive update on current theories regarding the mechanisms of metabolic dysfunction in IIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.